-
Merck obesity drug shows weight loss in study
Mar 31, 08 Clinical UpdatesMerck & Co said on Monday that patients on its experimental obesity drug lost more than twice as much weight as those on a placebo in a late-stage clinical study.
Patients on taranabant lost an average of 14.5 pounds (6.6 kilograms) compared with 5.7 lbs (2.6 kg) for those on a placebo after 52 weeks—a difference deemed statistically significant, Merck said in a statement.
The findings were presented at the American College of Cardiology conference in Chicago.
NEW YORK (Reuters)
Also in this section:
Subscribe to the "News" RSS Feed
TOP ۞